CD4 and neoplasm: As our interest was in defining tumor antigen-reactive TCR clonotypes, we evaluated CDR3 Vβ sequences recovered by TCR-seq from sorted CD8+ (total n=1695) and CD4+ (total n=1755) T cells from PBMC expanded with neoantigen-specific peptide.